Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
3 Altcoins to Watch in Fourth Week of October 2026 — ONDO, ALGO, and INJ

3 Altcoins to Watch in Fourth Week of October 2026 — ONDO, ALGO, and INJ

CryptonewslandCryptonewsland2026/10/25 18:57
By:Cryptonewsland
  • ONDO: Breakout recovery continues, with $0.589 standing as the next key target.
  • ALGO: Bulls challenge neckline resistance, aiming for a breakout above $0.132.
  • INJ: Rising momentum supports a potential move above the crucial $8.55 barrier.

Three promising altcoins are showing stronger chart structures as October moves into the final stretch. Price action across parts of the market suggests buyers are becoming more active after weeks of consolidation. While broader sentiment remains important, a few projects are approaching key technical levels that could shape near-term direction. Among them, ONDO, ALGO, and INJ stand out due to breakout setups, rising momentum, and important resistance zones now coming into view.

Ondo Finance (ONDO)

3 Altcoins to Watch in Fourth Week of October 2026 — ONDO, ALGO, and INJ image 0 Source: Trading View

Ondo Finance has started to regain strength after breaking above a descending channel that limited upside movement for months. Bulls also pushed price above a cup-and-handle formation, which often signals growing demand. A successful retest added confidence to the recovery and helped support the current trend. Right now, ONDO is challenging resistance near $0.5246. A daily close above that level could attract additional buying pressure. The next major obstacle sits around $0.589. Buyers need a firm break above that area to strengthen bullish conditions. If momentum continues, attention could shift toward the $0.6957 region. On the downside, a loss of support above $0.5246 may lead to further consolidation.

Algorand (ALGO)

3 Altcoins to Watch in Fourth Week of October 2026 — ONDO, ALGO, and INJ image 1 Source: Trading View

Algorand has climbed back into a major resistance zone that has repeatedly blocked advances this year. Earlier, price failed to complete a double-bottom breakout, which triggered a modest pullback. Even so, current market structure points to continued interest from buyers. The chart suggests a transition from accumulation toward expansion. Consecutive higher highs and higher lows continue to form along a rising trendline, which reflects improving momentum. A decisive move above the $0.13 to $0.132 neckline area would provide stronger confirmation of a breakout. If that happens, ALGO could target $0.146 before testing broader resistance near $0.19. Strong volume remains important because buyers must show commitment once price clears the neckline.

Injective (INJ)

3 Altcoins to Watch in Fourth Week of October 2026 — ONDO, ALGO, and INJ image 2 Source: Trading View

Injective continues to build a constructive setup on the daily chart. Rising support has helped sustain recovery efforts, while resistance near $8.55 remains the key barrier for bulls. Several breakout attempts have stalled near that zone since May. Technical indicators are becoming more supportive. Selling pressure appears to be fading, and MACD signals are moving closer to a bullish crossover. At the same time, On-Balance Volume continues to trend upward, which suggests improving participation from buyers. A convincing move above $8.55 could open the path toward $9.83 and potentially beyond $10. However, another rejection may keep price trapped below resistance for longer.

ONDO, ALGO, and INJ each approach important technical levels heading into the fourth week of October. ONDO aims to extend a recent breakout, while ALGO seeks confirmation above a key neckline. INJ continues to build pressure beneath long-standing resistance. Traders will likely watch volume and breakout strength closely as these setups develop.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23

Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market

Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.

智通财经•2026/11/06 12:37
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market